We want to transform the world's approach towards stemming the rise and spread of drug-resistant infections. Antibiotics are a vital part of modern medicine but their overuse and inappropriate use in humans and animals has caused one of the most urgent global health problems.
We set priority areas where we want to see, lead and be accountable for change.
This priority area will not involve funding calls.
Through our schemes, we will continue to fund a breadth of science research.
Follow us on Twitter @Wellcome_AMRExplore other priority areas
If we act now, we can minimise the threat of drug-resistant infections, saving millions of lives and safeguarding the medical progress of the past hundred years for future generations. If we don’t, then routine medical procedures and operations will become dangerous or cease to be effective.
Through this priority area we want to:
We already fund people with great ideas for tackling drug-resistant infections, so this priority area is not a funding call. It’s an opportunity for us to build on the work of the innovative people we support, and take action to make sure infectious diseases can be treated in the future.
For the latest news and views on all aspects of antimicrobial resistance, follow us on Twitter @Wellcome_AMR
In 2016, the 193 member states of the United Nations unanimously passed a resolution to tackle drug-resistant infections, calling for a coordinated international response.
To help sustain this global action:
There have been decades of under-investment in antibiotic discovery and development because of the cost and complexity of developing new antibiotics, combined with unfavourable market conditions. The result is that there aren’t enough new drugs in the antibiotics pipeline to replace those which are becoming ineffective.
To change this, Wellcome is helping to fund CARB-X, a public-private partnership which is dedicated to accelerating antibacterial research. The partnership aims to fill the current dearth of investment by providing up to $500 million over the next five years. Find out about CARB-X's top achievements so far.
In addition, we:
Drug-resistant infections don’t stop at borders. That’s why we want to help transform the way countries track, share and analyse information about the rise and spread of superbugs.
The Surveillance and Epidemiology of Drug-resistant Infections Consortium (SEDRIC) brings together international experts to share expertise and identify the gaps in drug-resistant infection surveillance and epidemiology. Applications to join the consortium are now open.
Other areas we're focusing on:
Clinical trials for new treatments for infectious diseases are long, expensive and inefficient. Up to 300 hospitals have to get involved to run a trial for each new treatment.
With partners, we’re looking at how to design and build clinical trial networks that have standardised processes.
We believe this approach could save $300 million and reduce the time needed to achieve regulatory approval for new products by at least two years.
Key outcomes from the second Call to Action on Antimicrobial Resistance held in Ghana, co-hosted by the Governments of Ghana, Thailand and the UK, along with the World Bank, UN Foundation and Wellcome.
The Ghana Declaration signed by the co-hosts of the Call to Action on Antimicrobial Resistance, together with civil society leaders, heads of private sector companies and the World Health Organization, the Food and Agriculture Organization and the World Organisation for Animal Health.
We respond to the draft recommendations of the Ad hoc Interagency Coordination Group on Antimicrobial Resistance.
This scientific white paper looks at the evidence about how antimicrobial resistance in the environment is impacting human health, and at how the risks can be addressed.
It summarises discussions from the International Environmental AMR forum, held in April 2018. Read the executive summary [PDF 638KB] for the key messages.
The progress CARB-X has made towards accelerating antibacterial research since it was established in 2016.
This report, commissioned by Wellcome and produced by Boston Consulting Group, looks at the opportunities and challenges around developing vaccines to combat antimicrobial resistance.
The evidence we submitted to the Health and Social Care Committee Antimicrobial resistance inquiry.
Recommendations from a pilot project to openly publish human antimicrobial resistance surveillance data generated and collected by the pharmaceutical industry. The project was led by the Open Data Institute and funded by Wellcome.
The key outcomes from the Call to Action on Antimicrobial Resistance event, organised by Wellcome in partnership with the UK, Ghanaian and Thai governments and the UN Foundation.
The event focused on the critical gaps in tackling the spread of drug-resistant infections and sought commitments to concerted and tangible actions.
A reflection on the activities and accomplishments of the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) in its first year, and plans for the next 12 months.
See all of our reports on drug-resistant infections.
Highly drug-resistant bugs are no longer a future problem. After decades of complacency, urgency is needed, says Wellcome’s Jeremy Knox in The Guardian.
We join international experts to call for a review of the global language used to discuss the problem of pathogens resistant to available drugs.
See more of our articles on drug-resistant infections.
We're working closely with other experts and partner organisations, including research and policy experts, clinical scientists, product developers, non-governmental organisations and other funders.
Our strategic advisory board provides guidance on this priority area.
If you have any questions or comments, contact the team: email@example.com.
Get the latest news about Wellcome and the work we fund in a monthly email.
Thank you. If this is the first time you have subscribed to a newsletter from Wellcome, you will receive an email asking you to confirm your subscription.